Nutra Pharma

Nutra Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nutra Pharma (NPHC) as of Oct 30, 2026 is -1.46 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -878,421.00 USD — a change of 66.47% (lower).

EBITDA

-1.46 MUSD

YoY

66.47%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nutra Pharma is 2025 -1.46 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nutra Pharma was 2024 -878,421.00 USD. It decreases by 66.47% lower compared to the previous year.

The Nutra Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.88 M USD
Jan 1, 2019
-1.23 M USD
Jan 1, 2020
-1.17 M USD
Jan 1, 2021
-1.92 M USD
Jan 1, 2022
-1.84 M USD
Jan 1, 2023
-781,514.00 USD
Jan 1, 2024
-878,421.00 USD
Jan 1, 2025
-1.46 M USD
The Nutra Pharma EBITDA history
YEAREBITDAYoY
-1.46 MUSD+66.47%
-878,421.00USD+12.40%
-781,514.00USD-57.42%
-1.84 MUSD-4.40%
-1.92 MUSD+64.38%
-1.17 MUSD-5.02%
-1.23 MUSD-34.54%
-1.88 MUSD+35.96%
-1.38 MUSD-167.63%
2.04 MUSD-64.56%
5.77 MUSD+161.83%
2.20 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nutra Pharma Stock analysis

What does Nutra Pharma do? Nutra Pharma is an American biotechnology company specializing in researching, developing, and marketing medications for the treatment of neurological, autoimmune, and cancer diseases. The company was founded in 2000 and is headquartered in Coral Springs, Florida. Nutra Pharma initially focused on developing dietary supplements for joint pain and inflammation relief. However, in 2004, the company made a significant breakthrough with the introduction of Nyloxin, a natural pain reliever made from a unique combination of toxins from marine animals such as bees, snakes, and spiders. Nyloxin aims to provide a safe and effective alternative to conventional pain medications like ibuprofen and opioids. In addition to Nyloxin, Nutra Pharma also offers several other products including Sinus Buster, a nasal spray designed to alleviate headaches and migraines, and Pet Pain, a veterinary pain medication for pets. The company is also involved in the research and development of therapeutics for autoimmune diseases like multiple sclerosis and HIV. Nutra Pharma holds patents for its novel drugs and drug candidates, including its ReceptoPharm platform technology currently being utilized in Alzheimer's disease drug development. The company has built a wide network of distribution partners to market its products in the United States and other countries. It also employs an aggressive marketing strategy to raise awareness among physicians, pharmacists, veterinarians, and end consumers. Additionally, Nutra Pharma supports nonprofit organizations dedicated to researching and developing therapeutics for rare and incurable diseases. Overall, Nutra Pharma has become a significant player in the biotechnology industry, developing innovative products and technologies for pain, inflammation, and various diseases. The company has established itself as a valuable partner to distribution partners and nonprofit organizations, benefiting from its expertise and products. Nutra Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nutra Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nutra Pharma is -1.46 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nutra Pharma changed from -878,421.00 USD to -1.46 M USD, representing a 66.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nutra Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nutra Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nutra Pharma

All Key Metrics — Nutra Pharma